Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/25/2025

Management of Sulfonylureas in Diabetes

Introduction to Sulfonylureas

  • The American Diabetes Association recommends using sulfonylureas with a shorter duration of action, such as glipizide, instead of glyburide, especially in older adults, due to increased hypoglycemia risk 1
  • Glipizide is preferred over glyburide, particularly in elderly patients, those with renal impairment, patients with a history of hypoglycemia, and those at high risk for severe consequences of hypoglycemia, according to the American Diabetes Association 1

Patient Populations at High Risk

  • Patients with renal dysfunction (creatinine clearance less than 50 mL/min) are at high risk when taking glyburide, and glipizide is preferred in this population 1
  • Debilitated or malnourished patients, those with adrenal or pituitary insufficiency, patients taking beta-blockers, and those with inconsistent caloric intake or who consume alcohol are also at high risk for hypoglycemia when using sulfonylureas 1
  • Older adults are at higher risk for hypoglycemia with sulfonylureas, and guidelines recommend using glipizide with caution in this population, with preference for shorter-acting agents 1, 2

Drug Interactions and Monitoring

  • Drug interactions, particularly with antimicrobials like fluoroquinolones and sulfamethoxazole-trimethoprim, can increase hypoglycemia risk in patients taking glipizide or glyburide, and should be monitored closely 1
  • Patients converted from glyburide to glipizide may experience a slight increase in A1c but with significantly reduced hypoglycemia risk 1
  • When adding other glucose-lowering agents to glipizide, the American College of Cardiology recommends considering reducing the glipizide dose, which may also apply to other combinations 3
  • Blood glucose should be monitored more frequently, especially during initiation of the combination, to assess the risk of hypoglycemia, and patients should be educated about symptoms of hypoglycemia and appropriate management 3

Special Considerations

  • Glipizide does not have active metabolites that rely on kidney elimination, unlike first-generation sulfonylureas, making it a preferred option in patients with renal impairment 4
  • Patients with renal impairment may have altered drug clearance, potentially affecting both glipizide and other medications, although glipizide is preferred over other sulfonylureas in renal impairment 4
  • The strength of evidence for the interaction between glipizide and other medications, such as NMN, is low due to the lack of direct clinical studies, and clinicians should approach these combinations with caution, particularly in patients at higher risk for hypoglycemia 5